|04/28/16||Portola Pharmaceuticals to Announce First Quarter 2016 Financial Results and Host Conference Call on Thursday, May 5|
|SOUTH SAN FRANCISCO, Calif., April 28, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. (Nasdaq:PTLA) announced today that it will host a webcast and conference call to discuss the Company’s financial results for the quarter ended March 31, 2016, and provide a general business overview on Thursday, May 5, 2016, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).
Conference Call Details
To access the live conference call, please dial (844) 452-6828 from the U.S. and Canada or +1 (765) 5... |
|04/14/16||Portola Pharmaceuticals Announces Upcoming Cerdulatinib Data Presentation at American Association for Cancer Research (AACR) Annual Meeting 2016|
|SOUTH SAN FRANCISCO, Calif., April 14, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that new data from a pharmacokinetic modeling study designed to identify the dose of cerdulatinib for expansion cohorts in a Phase 2 study will be presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2016, which is taking place from April 16-20 in New Orleans.
Cerdulatinib is an oral, dual Syk/JAK kinase inhibitor in development t... |
|04/06/16||Portola Pharmaceuticals Announces Presentation of Phase 3 APEX Study Results at International Society on Thrombosis and Haemostasis (ISTH) SSC Meeting 2016 on May 27, 2016|
|SOUTH SAN FRANCISCO, Calif., April 06, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that data from its Phase 3 APEX Study of betrixaban will be presented at the International Society on Thrombosis and Haemostasis (ISTH) 62nd Annual SSC (Scientific and Standardization Committee) Meeting, which is taking place from May 25-28 in Montpellier, France. Portola is developing betrixaban, an oral Factor Xa inhibitor anticoagulant, for the prevention of venous thromboem... |
|04/04/16||Portola Pharmaceuticals Enters Into Clinical Collaboration Agreement with Daiichi Sankyo to Develop Andexanet Alfa with Edoxaban in Japan|
|Development and Commercialization of Andexanet Alfa In Japan Fully Supported by Collaboration Partners
SOUTH SAN FRANCISCO, Calif., April 04, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (NASDAQ:PTLA), announced today that it has entered into a clinical collaboration agreement with Daiichi Sankyo to develop andexanet alfa as an antidote for edoxaban, Daiichi Sankyo’s Factor Xa inhibitor, in Japan.
Portola is developing andexanet alfa, a U.S. Food and Drug Administration (FDA)-designated... |
|03/24/16||Portola Pharmaceuticals Announces Topline Results from Phase 3 APEX Trial of Betrixaban for Prevention of Blood Clots in Acute Medically Ill Patients|
|—Full Data Set to be Presented at International Society of Thrombosis and Haemostasis (ISTH) Congress in May—
—Company to Hold Conference Call Today at 8:30 am ET—
SOUTH SAN FRANCISCO, Calif., March 24, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced topline data from the Phase 3 APEX (Acute Medically Ill VTE Prevention with Extended Duration Betrixaban) Study, which evaluated the superiority of extended-duration anticoagulation with oral betrixaban compared wi... |